Together We Can Stop...

Together We Can Stop Diabetes

Expanding Research to Advance Treatment and a Cure

Robert E. Ratner, MD FACP, FACE, Chief Scientific & Medical

Officer

Tamara Darsow, PhD Vice-President of Research

Tamara Darsow, PhD Vice-President of Research

Betsy Seaquist, MD Vice President, Medicine and Science

John Anderson, MD President-Elect, Medicine and Science

Vivian Fonseca, MD President, Medicine and Science

Sam Dagogo-Jack, MD Chair, Research Grant Review and BOD member

Al Powers, MD Chair, Research Policy Committee

Vincent Poitout, PhD, DVM Research Policy Committee and BOD member

Strategic Objective for Research Expand the field of diabetes research to accelerate

progress toward a cure and improved treatments

By the end of 2015: • Increased number of career development award

recipients who receive subsequent federal funding in the field of diabetes research

• Increased federal funding for diabetes research • Increased Association funding for diabetes research

The American Diabetes Association has been supporting diabetes research in the academic community for more

than half a century, significantly contributing to the diabetes research landscape.

Since inception of the Program in 1952

– Nearly 4,000 research projects have been funded

– More than $600 million has been invested in diabetes research

In 2011 the Program supported: – Nearly $34.6 million in diabetes research

– More than 400 active research projects

– 139 leading academic research institutions

Research Program Successes

• Publications per award 6

• Receive patents 17%

• Receive promotions 56%

• Remain in diabetes research 98%

• Receive recognition awards 47%

85% of investigators received subsequent federal funding to support their work Investigators leveraged Association support into a 7.5 fold increase in funding from other sources Association funding provides the seed for expanding the field of diabetes research

Research Program Successes Panel

Sam Dagogo-Jack, MD

Chair, Research Grant Review and BOD member

Al Powers, MD

Chair, Research Policy Committee

Vincent Poitout, PhD, DVM

Research Policy Committee and BOD member

Kenneth Cusi, MD University of Florida College of Medicine Clinical Translational Award

Role of Early Screening and Intervention for Fatty Liver Disease (NAFLD) in a Predominantly Hispanic Population with Type 2 Diabetes Mellitus (T2DM)

Chih-Pin Liu, Ph.D. City of Hope, Beckman Research Institute

Basic Science Award

Tolerance Induction and Inhibition of Type 1 Diabetes

Alyssa H. Hasty, Ph.D. Vanderbilt University Medical Center

ADA-Ethicon Endosurgery/Covidien Research Award in Bariatric Surgery and Diabetes

Impact of Bariatric Surgery on Resolution of Inflammation in Adipose Tissue

I’m Here to Stop Diabetes

Robert E. Ratner, MD FACP, FACE, Chief Scientific & Medical

Officer

Communication and Translation

Accelerating Research Advances to Patients

Research is Central to the Mission

Professional Resources Scientific Sessions

Professional education Peer-reviewed journals

DiabetesPro

Medical Information Clinical Practice Recommendations

(treatment guidelines) Medical publications

Advocacy Research support

Diabetes prevention and care Legal advocacy and support

Legislative action

Communities Community health education programs

Center for Information & Community Support

Forecast magazine Diabetes.org

RESEARCH Direct research

funding

US Diabetes Therapeutic Advances

GLP-1R agonist

1920 1990 2000 2010 1970

Insulin SFU

Pramlintide

DPP-4

Bromocript

1960 1980

1st ADA Standards of Care 1989

TZD

αGlucosidase inhibitor

Metformin

Rapid-acting insulin

Meglitinide

Basal insulin

Transformation of Diabetes Management

• Beef/Pork Insulin and SFUs

• Average HbA1c ~ 9%

• Complications -common, etiology not clear

• ADA treatment algorithm

• Multiple oral/injection options

• Average HbA1c ~ 7.5%

• Complications -less frequent, etiology(ies) well-defined

1980 2012

Type 2 Diabetes

Transformation of Diabetes Management

1980 2012

Type 1 Diabetes

• Animal Insulins

• Average HbA1c >9%

• Life Expectancy-reduced

• Hypoglycemic Episodes

• Minimal Monitoring Methods

• Complications

• Childbearing?

• Human and analog insulins, pens or pumps, basal and mealtime

• CGMS, Self Glucose Monitoring

• Average HbA1c < 8%

• Life Expectancy-near normal

Professional Journals

Diabetes Basic Research with circulation of 5,000

Rank 1st among diabetes journals, Impact factor of 8.3

2.3 million online visits with 5.5 million total page views

Diabetes Care Clinical Research with circulation of 12,000

Rank 2nd among diabetes journals, Impact factor

Clinical Diabetes – Target audience of primary care physicians – Circulation: 29,000 – 713,000 online visits with 1.3 million page

views Diabetes Spectrum

– Target audience of diabetes educators, NPs, and other HCP

– Circulation: 5,500 – 550,000 online visits with 920K total page

views

Professional Journals

Translation of Research Findings

Betsy Seaquist, MD

Vice President, Medicine and Science

John Anderson, MD

President-Elect, Medicine and Science

Vivian Fonseca, MD

President, Medicine and Science

I’m Here to Stop Diabetes